

Conference Day One

Thursday 25th January 2007

08.30 · [Coffee and registration](#)

09.00 · [Chairman's opening remarks](#)

09.15 · [Why Drugs Fail, A Study on Side Effects in New Chemical Entities](#)

Prof. Thierry Langer

Faculty of Chemistry and Pharmacy
Universität Innsbruck

10.00 · [Predicting Unwanted Medicine Side Effects Early in the Drug Development Process](#)

Prof. Kevin Park

Head of Department
Department of Pharmacology & Therapeutics
University of Liverpool

10.45 · [Networking coffee break](#)

11.15 · [A Biochemical Approach to Predictive *In Vitro* Toxicity Screening Provides *In Vivo* Relevance Early in the Drug Discovery Process](#)

James McKim

President & CEO
CeeTox, Inc

12.00 · [Company Presentations](#)

12.45 · [Networking lunch](#)

14.15 · [Accurate Alternatives to Animal Testing in Regards to In Vitro Acute Toxicity Tests Being More Predictive Than Animal Tests](#)

Dr. Myriam Fabre

Director, Services & Reagents
Advanced In Vitro Cell Technologies

15.00 · [Global In Vitro Predictive Stem Cell Hemotoxicology for Early Drug Screening, Safety Assessment and Estimating Pre-Clinical and Human Clinical Trial Dosing](#)

Dr. Ivan N. Rich

Chairman & CEO
HemoGenix, Inc

15.45 · [Coffee break](#)

16.00 · [Histomics, A Novel Method for Detecting and Validating Urinary Biomarkers](#)

Dr. Frank Falkenberg
Professor of Immunology
Ruhr-Universität Bochum
Director/Founder
Cires Cell + Immune research

16.45 · [Toxicogenomics and Predictive Toxicology](#)

Dr. Bill Mattes
Director, Toxicology
The Critical Path Institute

17.30 · [Chair's Closing Remarks](#)

18.00 · [End of Day One](#)

Conference Day Two

Friday 26th January 2006

08.30 · [Coffee and registration](#)

09.00 · [Chairman's opening remarks](#)

09.15 · [High Throughput Screening for In Vitro Toxicity Testing](#)

Dr. Willem Schoonen
Group Leader Pharmacology
NV Organon

10.00 · [Using Primary Hepatocytes for Cytotoxicity Studies](#)

Dr. Albert P. Li
President and CEO
Advanced Pharmaceutical Sciences

10.45 · [Networking coffee break](#)

11.15 · [In Vitro Hepatotoxicity Assays in Drug Development](#)

Dr. Nicky Hewitt
European Scientific Consultant
Cellz Direct

12.00 · [Microscale Human Liver Tissue for Drug Development](#)

Dr. Sangeeta Bhatia
Director, Laboratory for Multiscale Regenerative Technologies
Massachusetts Institute of Technology

12.45 · [Networking lunch](#)

14.15 · [Cell-based Models to Study Hepatic Drug Metabolism and Enzyme Induction in Humans](#)

Dr. Willem Meuldermans
Global Sr. Preclin.PK Expert
Johnson & Johnson

15.00 · [Using Cytochrome P450 \(CYP450\) Isozyme Assays to Determine Affects on Human Drug Metabolism](#)

Dr. Drew Niles
R&D Scientist, Cellular Analysis
Promega Corporation

15.45 · [Coffee break](#)

16.00 · [Mutagenicity/Embryotoxicity](#)

Dr. Aldert Piersma
RIVM The Netherlands

16.45 · [Systems-ADME/Tox: Resources and Network Approaches](#)

Dr. Tatiana A. Nikolskaya
Chief Scientific Officer
Gene Go

17.30 · [Panel Discussion](#)

This session will provide an opportunity for all day two speakers and delegates to explore key issues that have arisen over the day.

18.00 · [Closing Comments from the Chair](#)

18.30 · [Close Conference](#)